{
  "id": "62513dc6e764a53204000014",
  "type": "summary",
  "question": "What is Upadacitinib?",
  "ideal_answer": "Upadacitinib is an oral Janus kinase inhibitor approved for the treatment of rheumatoid arthritis (RA) and recently approved by the European Medicines Agency for the treatment of psoriatic arthritis (PsA).",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/34551039",
    "http://www.ncbi.nlm.nih.gov/pubmed/32648334",
    "http://www.ncbi.nlm.nih.gov/pubmed/34464029"
  ],
  "snippets": [
    {
      "text": "upadacitinib, an oral Janus kinase 1 selective inhibitor",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32648334",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A number of Janus kinase (JAK) inhibitors (tofacitinib, filgotinib, upadacitinib) ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34551039",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}